Pages that link to "Q79945430"
Jump to navigation
Jump to search
The following pages link to Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation (Q79945430):
Displaying 50 items.
- Fifty years of melphalan use in hematopoietic stem cell transplantation (Q26824498) (← links)
- Interpreting outcome data in hematopoietic cell transplantation for leukemia: tackling common biases. (Q30884173) (← links)
- NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes (Q33393647) (← links)
- Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML. (Q33684432) (← links)
- Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study (Q33737884) (← links)
- Hematopoietic stem cell transplantation for MDS. (Q33767314) (← links)
- Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome (Q33813439) (← links)
- Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan (Q33841438) (← links)
- Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia (Q33861150) (← links)
- Reduced-intensity conditioning transplantation in myeloid malignancies (Q33955590) (← links)
- Challenges in treating older patients with acute myeloid leukemia (Q33985549) (← links)
- Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia (Q33990856) (← links)
- NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Tr (Q34044024) (← links)
- Allogeneic hematopoietic cell transplantation: the state of the art (Q34145155) (← links)
- Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies (Q34284225) (← links)
- Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamide (Q34316871) (← links)
- Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis (Q34360641) (← links)
- Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome (Q34388640) (← links)
- The role of azacitidine in the management of myelodysplastic syndromes (MDS). (Q34418429) (← links)
- Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies (Q34463645) (← links)
- Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. (Q34505185) (← links)
- Fludarabine, cyclophosphamide, and antithymocyte globulin for matched related and unrelated allogeneic stem cell transplant in severe aplastic anemia (Q34545908) (← links)
- Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience (Q34549230) (← links)
- Phase 1/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies (Q34568898) (← links)
- Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results (Q34575857) (← links)
- Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life (Q34667853) (← links)
- Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR (Q35060676) (← links)
- Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes (Q35142616) (← links)
- Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial. (Q35193735) (← links)
- Who is fit for allogeneic transplantation? (Q35660739) (← links)
- Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT. (Q35800814) (← links)
- Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings (Q35838113) (← links)
- Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of th (Q35849045) (← links)
- Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning (Q36002866) (← links)
- Cellular immune therapy for refractory cancers: novel therapeutic strategies (Q36003215) (← links)
- Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies (Q36173285) (← links)
- Reduced-intensity allogeneic hematopoietic stem cell transplantation for acute leukemias: 'what is the best recipe?'. (Q36182976) (← links)
- Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis (Q36206849) (← links)
- Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients (Q36264692) (← links)
- Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting. (Q36341861) (← links)
- Topics in pediatric leukemia--hematopoietic stem cell transplantation. (Q36348606) (← links)
- Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how? (Q36431041) (← links)
- Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning (Q36548358) (← links)
- Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents (Q36548362) (← links)
- Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct (Q36548370) (← links)
- Optimization of allogeneic transplant conditioning: not the time for dogma (Q36556498) (← links)
- Novel approaches in allogeneic stem cell transplantation (Q36562204) (← links)
- Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and mu (Q36608468) (← links)
- Allogeneic stem cell transplantation as treatment for myelofibrosis (Q36609417) (← links)
- Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT. (Q36687119) (← links)